Sun, X., Roudi, R., Dai, T., Chen, S., Fan, B., Li, H., Zhou, Y., Zhou, M., Zhu, B., Yin, C., Li, B. and Li, X. (2019) Immune-Related Adverse Events Associated with Programmed Cell Death Protein-1 and Programmed Cell Death Ligand 1 Inhibitors for Non-Small Cell Lung Cancer: A PRISMA Systematic Review and Meta-Analysis. BMC Cancer, 19, Article No. 558.
https://doi.org/10.1186/s12885-019-5701-6

has been cited by the following article:

• TITLE: Pembrolizumab-Induced Steven-Johnson Syndrome in an NSCLC Patient: A Case Report

  AUTHORS: Shan Su, Xinxing Hu, Hongzhong Yang

  KEYWORDS: Pembrolizumab, Non-Small Cell Lung Cancer, Immune-Related Cutaneous Adverse Event, Steven-Johnson Syndrome

  JOURNAL NAME: Health, Vol.14 No.1, January 18, 2022

  ABSTRACT: Background: Immune checkpoints inhibitors (ICIs) are widely used in various therapy of tumors. With the increasing usage of them, immune-related adverse events (irAEs) have been known and become common events, especially in the dermatologic system. However, the rare and severe immune-related cutaneous adverse events (irCAEs) still lack enough knowledge. Case presentation: We described a rare case of Steven-Johnson syndrome (SJS) induced by pembrolizumab in an advanced squamous non-small cell lung cancer (NSCLC) patient. SJS is a rare irCAE that could happen at any time after immunotherapy while this case happened from the 3rd day. The patient had influence-like symptoms and several mucous lesions including oral, eye, and skin. With a gradually severer condition, a stoss therapy of intravenous immunoglobulin (IVIG) had a mild effect. It was a long process and failed to respond to usual dermatologic treatment. Conclusion: We share this case in order to enhance clinicians’ ability to early recognition and diagnosis in severe irCAEs. Early recognition and appropriate management are important to evade the termination of immunotherapy. Such severe irCAE should be paid more attention to in clinical medicine when using ICIs.